LYCOS RETRIEVER 
Genetics: Myriad Genetics
built 624 days ago
SALT LAKE CITY, Nov. 7 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) today reported financial results for the first quarter of fiscal 2007. For the three-month period ended September 30, 2006, molecular diagnostic revenue increased to $30.9 million from $21.5 million in the same quarter of the prior year, an increase of 43%. Molecular diagnostic revenue for the first fiscal quarter ... experienced a $2.0 million increase over the previous quarter ended June 30, 2006. The majority of this growth resulted from increased sample volumes and accelerated market penetration across all four product lines.
Source:
SALT LAKE CITY, Jan. 13 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today announced progress with its anti-cancer compound, MPI-176716. The drug candidate is in the final stages of preclinical development prior to submission to the FDA as an Investigational New Drug (IND). The new data released by the Company demonstrates the drug's exceptional potency in killing cancer cells and its ability to cause tumor regression in animal models of ovarian cancer.
Source:
Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.
Source:
SALT LAKE CITY, March 23 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has elected Dennis Langer, M.D., J.D., to its Board of Directors. Dr. Langer's term is effective as of May 1, 2004.
Source:
MORE ABOUT
Myriad Genetics